In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]-epidepride single photon emission tomography (SPET) study

British Journal of Psychiatry

Volumn 175, Issue SEPT., 1999, Pages 231-238

  Bigliani, Valeria ^a   Mulligan, Rachel S ^b   Acton, Paul D ^b   Visvikis, Dimitris ^b   Ell, Peter J ^b   Stephenson, Caroline ^a   Kerwin, Robert W ^a   Pilowsky, Lyn S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EPIDEPRIDE; IODINE 123; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; FEMALE; HUMAN; IN VIVO STUDY; MALE; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 0032817821     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.175.3.231     Document Type: Article

References (30)

1. Alcohol, Drug Abuse, and Mental Health Administration (1974) Abnormal Involuntary Movements Scale (AIMS) Washington, DC: Department of Health. Education and Welfare.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV).Washington, DC: APA.
3. Andreasen, N. C. (1983) Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa.
4. _ (1984) Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa.
5. Barnes,T. R. E. (1989) A rating scale for druginduced akathisia. British Journal of Psychiatry, 154, 672-676.
6. 2 blockade by typical and atypical neuroleptics. Lancet, 339, 497.
7. 2 sites. Neuroscience, 28, 275-290.
8. Endicott, J., Spitzer, R. L., Fleiss, J. L., et al (1976) The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbances. Archives of General Psychiatry, 33, 766-771.
9. 2 Dopamine receptors in neuroleptic-naive schizophrenic patients. Archives of General Psychiatry, 47, 213-219.
10. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Archives of General Psychiatry, 49, 538-543.
11. 2 dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology, 133, 396-404.
12. 125l-epidepride. Synapse, 23, 115-123.
13. 11C]-raclopride binding, journal of Cerebral Blood Flow and Metabolism, 18, 941-949.
14. 2 receptor occupancy with low dose haloperidol treatment: a PET study. American Journal of Psychiatry, 153, 948-950.
15. 2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology, 131, 148-152.
16. 125l-epidepride. Brain Research, 609, 237-243.
17. 123l]-epidepride: characterization of uptake in the human brain, Journal of Neural Transmission, 101, 95-103,
18. 2 dopaminergic receptors in the primate cerebral cortex. Proceedings of the National Academy of Sciences USA, 91, 4353-4356.
19. 16Br-bromolisuride. British Journal of Psychiatry, 158, 346-350.
20. 2 dopamine receptor occupancy in relation to antipsychotic drug effect: a double blind PET study of schizophrenic patients, Biological Psychiatry, 33, 227-235.
21. Overall, J. & Gorham, D. E. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799-812.
22. Peroutka, S. J. & Synder, S. H. (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. American Journal of Psychiatry, 137, 1518-1522.
23. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet, 340, 199-202.
24. 123I-IBZM SPET (single photon emission tomography study). Psychological Medicine, 23, 791-797.
25. 123I-IBZM single photon emission computerised tomography study. British Journal of Psychiatry, 164, 16-26.
26. _ , Mulligan, R., Acton, P., et al (1997) Limbic selectivity of clozapine. Lancet, 350, 490-491.
27. Pirker, W., Asenbaum, S., Wenger, S., et al (1997) Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. Journal of Nuclear Medicine, 38, 1711-1717.
28. Simpson, G. H. & Angus, J. W. S. (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica, 212 (suppl.), 11-19.
29. Taylor, D., Kerwin, R. & Duncan, D. (1996) The Maudsley Prescribing Guidelines (3rd edn). London: Bethlem and Maudsley NHS Trust.
30. 18F-N-methylspiperdol by extrastriatal dopamine receptors in schizophrenic patients. Synapse, 19, 14-17.